Acute Kidney Injury Market Report 2026

Acute Kidney Injury Market Overview

• Acute Kidney Injury market size has reached to $5.72 billion in 2025 • Expected to grow to $7.78 billion in 2030 at a compound annual growth rate (CAGR) of 6.3% • Growth Driver: Rising Diabetes Prevalence Fuels Growth Of The Market • Market Trend: FDA Approval Granted For Phase II Clinical Trial Of Novel Acute Kidney Injury Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Acute Kidney Injury Market?

Acute kidney injury (AKI) refers to a sudden decline in kidney function, leading to an accumulation of waste products, electrolytes, and fluids in the body. It can develop rapidly over hours or days and is often caused by conditions like reduced blood flow, direct kidney damage, or obstruction of the urinary tract. The main injury types of acute kidney injury are pre-renal kidney injury, post-renal kidney injury, and intrinsic kidney injury. Pre-renal kidney injury occurs when there's a significant drop in blood flow to the kidneys, leading to decreased filtration. It includes various treatments such as dialysis, drug therapy, and urinary implants, catering to end users including hospitals, ambulatory surgical centers, and others.

What Is The Acute Kidney Injury Market Growth Forecast?

The acute kidney injury market size is expected to see strong growth in the next few years. It will grow to $7.78 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to advancement in renal replacement therapies, development of novel nephroprotective drugs, expansion of ambulatory surgical centers, rising use of biomarkers for early detection, integration of ai-based monitoring systems in renal care. Major trends in the forecast period include increasing adoption of dialysis and drug therapies, rising incidence of acute kidney injury globally, growing focus on early diagnosis and biomarker development, expansion of urinary implant applications, integration of minimally invasive techniques in aki management.

What Is The Driver Of The Acute Kidney Injury Market?

Increased prevalence of diabetes is expected to propel the growth of the acute kidney injury market going forward. Diabetes refers to a group of metabolic diseases characterized by high blood sugar levels, either due to the body's inability to produce enough insulin or because cells do not respond properly to insulin. The increasing prevalence of diabetes is driven by factors such as rising obesity rates, poor diets, sedentary lifestyles, aging populations, and enhanced awareness and diagnosis. Acute kidney injury triggers metabolic and inflammatory changes that can influence insulin resistance and glucose homeostasis, highlighting a complex interplay that may impact diabetes progression and management. For instance, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, increased prevalence of diabetes is driving the growth of the acute kidney injury industry.

Key Players In The Global Acute Kidney Injury Market

Major companies operating in the acute kidney injury market are Fresenius Medical Care AG & Co. KGaA, Baxter International Inc., B. Braun Melsungen AG, Nipro Corporation, Nikkiso Co. Ltd., Asahi Kasei Medical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Quark Pharmaceuticals Inc., Kringle Pharma Inc., Aptabio Therapeutics Inc., AM-Pharma B.V., Arch Biopartners Inc., Guard Therapeutics International AB

Global Acute Kidney Injury Market Trends and Insights

Major companies operating in the acute kidney injury (AKI) market are focusing on obtaining regulatory approvals to enhance their product portfolios and offer novel treatment options. Regulatory approvals refer to the official authorization granted by regulatory bodies, such as the FDA or EMA, allowing a product to be marketed and sold after meeting safety, efficacy, and quality standards. For instance, in December 2023, Mission Therapeutics Ltd., a UK-based biotechnology company, received FDA approval to initiate a Phase II clinical trial for its lead asset, MTX652, targeting acute kidney injury (AKI) in patients at high risk following cardiac surgery. It is designed to target critical pathways involved in kidney injury and repair, aiming to reduce inflammation, prevent further kidney damage, and promote recovery. Its unique feature of this trial is its focus on leveraging novel therapeutic mechanisms to address the underlying molecular causes of AKI, which could offer more effective treatment options compared to existing interventions. The Phase II trial will evaluate MTX652’s safety, efficacy, and pharmacokinetics, providing crucial data that could support broader clinical adoption and potential approval.

What Are Latest Mergers And Acquisitions In The Acute Kidney Injury Market?

In October 2024, BioPorto A/S, a Denmark-based in vitro diagnostics company, partnered with Beckman Coulter, Inc., to broaden access to its acute kidney injury (AKI) diagnostic solutions. Through this partnership, Beckman Coulter will distribute BioPorto’s neutrophil gelatinase-associated lipocalin (NGAL) tests across its DxC and AU clinical chemistry analyzers, enabling wider adoption of early AKI detection tools. Beckman Coulter, Inc. is a US-based diagnostics company specializing in early detection solutions for acute kidney injury.

What Defines the Acute Kidney Injury Market?

The acute kidney injury market includes revenues earned by entities by providing services such as urinalysis & biomarker testing, imaging services, dialysis services, and surgical & interventional procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acute Kidney Injury Market Report 2026?

The acute kidney injury market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acute kidney injury industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.